Multidrug resistance (MDR) represents a serious global threat due to the rapid global spread
and limited antimicrobial options for treatment of difficult-to-treat (DTR) infections sustained …

Carbapenem resistance is a major global health problem that seriously compromises the
treatment of infections caused by nosocomial pathogens. Resistance to carbapenems …

Infections in the ICU are often caused by Gram-negative bacteria. When these
microorganisms are resistant to third-generation cephalosporines (due to extended …

ABSTRACT Imipenem (IMI)/cilastatin/relebactam (REL)(I/R) is a novel β-lactam/β-lactamase
inhibitor combination with expanded microbiologic activity against carbapenem-resistant …

ABSTRACT Introduction Carbapenem-resistant (CR) Pseudomonas aeruginosa infections
constitute a serious clinical threat globally. Patients are often critically ill and/or …

Introduction Novel last resort beta-lactam antibiotics are now available for management of
infections due to New-Delhi Metallo-Beta-Lactamase (NDM) producing Enterobacterales …

Background Carbapenem-nonsusceptible and multidrug-resistant (MDR) P. aeruginosa,
which are more common in patients with lower respiratory tract infections (LRTIs) and in …

Background Imipenem/relebactam is a novel carbapenem/β-lactamase inhibitor
combination, developed to act against carbapenemase-producing Enterobacterales (CPE) …

Pseudomonas aeruginosa is the microorganism most frequently involved in the main ICU-
acquired infections, with special importance in ventilator associated pneumonia. Its …

Scope Pseudomonas aeruginosa, a ubiquitous opportunistic pathogen considered one of
the paradigms of antimicrobial resistance, is among the main causes of hospital-acquired …